Photo credit: CC0 Public Domain
The legislation currently under consideration in the U.S. Congress would increase oversight of certain diagnostic tests, and a new study by researchers at Massachusetts General Hospital (MGH) and colleagues from several other institutions shows that their potential effects depend on the key details in the final Bill will depend on language. This study, published in JCO Oncology Practice, provides the first evidence-based analysis of how new rules for regulating laboratory-developed tests (LDTs) could affect healthcare costs in the United States.
“The idea of having more control over LDTs is justified,” says Dr. Jochen Lennerz, Medical Director of the MGH Center for Integrated Diagnostics (CID) and lead author of the study. “However, our results show that it is very important to align the language in this new law with the intent of what it is to achieve.”
From a regulatory perspective, there are two categories of in vitro clinical tests (IVCTs), which include diagnostic tests performed in a test tube, culture dish, or other location outside of a living organism. Prepared tests for a wide variety of conditions are available commercially. The Food and Drug Administration (FDA) strictly regulates these tests and requires manufacturers to submit marketing approval data before they can be sold. However, clinical laboratories in hospitals and other health care facilities can create their own IVCTs for in-house use called LDTs. Currently, the FDA does not require LDTs to be marketed and has little control over their use.
LDTs serve a variety of purposes, but a critical role is to identify patients for novel drug therapies that target specific DNA variations, especially when a commercial test is not yet available. This form of therapy, known as personalized medicine, is becoming increasingly important in cancer treatment.
Unfortunately, flawed IVCTs can lead to inaccurate results, leading some patients to forego potentially beneficial treatments and receive others from unnecessary and potentially harmful therapies. The proposed legislation, currently known as the Verifying Accurate and Leading-Edge IVCT Development (VALID) Act, illustrates the authority of the FDA over all diagnostic testing.
If passed, VALID would focus on what are known as highly complex IVCTs, which have the greatest potential for patient harm if the results are incorrect. To meet VALIDITY, clinical laboratories would need to demonstrate the accuracy of their LDTs, including a process known as technology certification.
Lennerz believes that the strict interpretation of the validity of VALID, which is not currently defined in the bill, will affect whether the proposed bill can improve the quality of LDTs without significantly increasing future health care costs increase. He joined lead author Richard Huang, MD, and several colleagues to model the total cost of maintaining the technology certification framework under VALID for cancer diagnostics. They based their estimates on 2019 data from CID, which performs more than 10,000 highly complex LDTs for MGH patients each year.
The study found that the maintenance cost for a lab performing this volume of LDT would be $ 638,000 per year with low stringency and slightly higher ($ 685,000) with moderate stringency, but to $ 1.2 million with very strict enforcement would rise. Extrapolating this data to reflect the additional costs for the country’s 886 cancer treatment centers and ensuring VALID compliance would reduce U.S. healthcare costs by $ 565 million, $ 606 million, or $ 1.1 billion over a three-year period . USD increase depending on strict enforcement.
Lennerz believes the study’s important contribution is to put a price tag on VALID, which no one has done before. “The most important finding is that there is a cost to maintain this new infrastructure,” he says.
And while these numbers may seem high to some, they should be kept in mind, says study co-author Jeff Allen, president and CEO of Friends of Cancer Research, a nonprofit patient advocacy organization in Washington, DC: US, We’re consistently seeing increases in healthcare spending in the region of $ 200 billion a year. “Even with additional FDA enforcement, VALID’s increased cost is less than 0.5% of its annual increase in spending, he notes firmly. “With the gain in assured quality in tests, the avoidance of medical errors and the improved support with medical decisions, the costs are offset. Most importantly, patient care will improve,” says Allen. VALID has bipartisan support in both houses of Congress, which is expected to begin debating the law in early summer.
Testing the accuracy of FDA-approved and laboratory-developed cancer genetics tests
Richard Huang et al., National Precision Diagnostic Maintenance Costs under the 2020 In Vitro Clinical Test Precise Development Review (VALID) Act, JCO Oncology Practice (2021). DOI: 10.1200 / OP.20.00862 Provided by Massachusetts General Hospital
Quote: The study models the economic impact of the proposed law to regulate high risk diagnostic tests (2021, April 21), accessed on April 21, 2021 from https://medicalxpress.com/news/2021-04-economic-impact-law-high- risk- diagnostik.html
This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.